The Women’s wellness after cancer program: a multisite, single-blinded, randomised controlled trial protocol

BMC Cancer

Table 4 Outcome measures, instruments, modes of administration, and time points of the study

Measures	Instruments		Time point		Mode of administration
		t ₀ (baseline)	t ₁ (12 weeks)	t ₂ (24 weeks)	Online survey	RA data collection
Background information
Socio-demographics
Medical and surgical history		X	Assesses changes in medical/surgical history, and medications since baseline			X
Cancer diagnosis and treatment		X				X
Medications		X				X
Subjective health indicators
HRQoL	FACT G [18]	X	X	X	X
	SF – 36 [41]	X	X	X	X
Depression	CES – D [42]
Anxiety	Zung SAS [43]
Sexuality
Sexual function	FSFI [44]	X	X	X	X
Exercise self-efficacy	ESE [45]	X	X	X	X
Dietary self-efficacy	DSE [45]	X	X	X	X
Menopausal symptoms
Menopausal symptoms	GCS [23]	X	X	X	X
Modifiable lifestyle factors
Diet	FFQ [46, 47]	X	X	X		X
Physical Activity	IPAQ [48]
Sleep	PSQI [27]
Waist and hip circumference		X	X	X		X
Cost effectiveness evaluation
Calendar of costs incurred		X	X	X		X

FACT G Functional Assessment of Cancer Therapy – General, SF – 36, Short Form 36, CES – D, Center for Epidemiologic Studies Depression Scale, Zung SAS Zung self-rating anxiety scale, FSFI Female Sexual Function Index, ESE Exercise Self-Efficacy, DSE Dietary Self-Efficacy, GCS Greene Climacteric Scale; FFQ Food Frequency Questionnaire, IPAQ International Physical Activity Questionnaire, PSQI Pittsburgh sleep quality index

ISSN: 1471-2407